
Pfizer (PFIZER) | Financial Analysis & Statements
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Mar 2025Income Metrics
Revenue
5.9B
Gross Profit
3.9B
65.79%
Operating Income
2.1B
35.66%
Net Income
3.3B
55.91%
Balance Sheet Metrics
Total Assets
49.1B
Total Liabilities
6.9B
Shareholders Equity
42.2B
Debt to Equity
0.16
Cash Flow Metrics
Revenue & Profitability Trend
Pfizer Income Statement From 2021 to 2025
Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|---|
Revenue | 22.8B | 21.9B | 24.2B | 26.1B | 22.4B |
Cost of Goods Sold | 8.1B | 8.0B | 8.8B | 9.5B | 8.0B |
Gross Profit | 14.7B | 14.0B | 15.5B | 16.6B | 14.4B |
Gross Margin % | 64.5% | 63.7% | 63.9% | 63.7% | 64.3% |
Operating Expenses | |||||
Research & Development | - | - | - | - | - |
Selling, General & Administrative | - | 2.6B | 2.4B | 2.8B | 2.4B |
Other Operating Expenses | 3.6B | 1.5B | 1.6B | 4.2B | 1.2B |
Total Operating Expenses | 3.6B | 4.1B | 4.0B | 7.0B | 3.6B |
Operating Income | 6.8B | 5.8B | 7.1B | 7.2B | 6.1B |
Operating Margin % | 29.8% | 26.3% | 29.3% | 27.6% | 27.2% |
Non-Operating Items | |||||
Interest Income | - | 1.7B | 854.9M | 489.4M | 387.4M |
Interest Expense | 84.1M | 107.3M | 133.9M | 104.9M | 151.1M |
Other Non-Operating Income | - | - | - | - | - |
Pre-tax Income | 10.2B | 7.5B | 8.2B | 7.7B | 6.7B |
Income Tax | 2.5B | 1.9B | 2.0B | 1.6B | 1.7B |
Effective Tax Rate % | 24.5% | 26.1% | 24.3% | 20.7% | 25.6% |
Net Income | 7.7B | 5.5B | 6.2B | 6.1B | 5.0B |
Net Margin % | 33.6% | 25.1% | 25.8% | 23.5% | 22.2% |
Key Metrics | |||||
EBITDA | 9.1B | 8.1B | 9.1B | 9.0B | 7.9B |
EPS (Basic) | - | ₹120.51 | ₹136.38 | ₹133.89 | ₹108.77 |
EPS (Diluted) | - | ₹120.51 | ₹136.38 | ₹133.89 | ₹108.77 |
Basic Shares Outstanding | - | 45750372 | 45750372 | 45750990 | 45750372 |
Diluted Shares Outstanding | - | 45750372 | 45750372 | 45750990 | 45750372 |
Income Statement Trend
Pfizer Balance Sheet From 2021 to 2025
Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|---|
Assets | |||||
Current Assets | |||||
Cash & Equivalents | 5.0B | 1.1B | 366.0M | 627.6M | 1.6B |
Short-term Investments | 23.1B | 19.1B | 18.0B | 15.5B | 9.4B |
Accounts Receivable | 1.9B | 1.9B | 1.5B | 1.2B | 1.1B |
Inventory | 4.8B | 4.3B | 4.2B | 4.5B | 4.4B |
Other Current Assets | 389.6M | 9.5M | 5.0M | 17.1M | 1.5B |
Total Current Assets | 35.1B | 27.7B | 25.3B | 24.0B | 19.1B |
Non-Current Assets | |||||
Property, Plant & Equipment | 1.7B | 1.5B | 1.8B | 0 | 1.9B |
Goodwill | 10.8B | 10.9B | 11.0B | 11.5B | 12.0B |
Intangible Assets | 243.1M | 342.7M | 442.3M | 945.5M | 1.4B |
Long-term Investments | - | - | - | - | - |
Other Non-Current Assets | 1.7B | 500.9M | 257.5M | 257.5M | 257.5M |
Total Non-Current Assets | 14.0B | 14.6B | 14.8B | 15.0B | 13.6B |
Total Assets | 49.1B | 42.3B | 40.0B | 39.0B | 32.7B |
Liabilities | |||||
Current Liabilities | |||||
Accounts Payable | 1.5B | 1.7B | 2.2B | 2.6B | 2.8B |
Short-term Debt | 407.8M | 401.9M | 411.5M | 392.5M | 632.3M |
Current Portion of Long-term Debt | - | - | - | - | - |
Other Current Liabilities | 647.6M | 938.5M | 708.8M | 2.3B | 2.2B |
Total Current Liabilities | 5.7B | 5.5B | 6.6B | 8.5B | 7.7B |
Non-Current Liabilities | |||||
Long-term Debt | 676.2M | 543.5M | 933.2M | 1.3B | 426.8M |
Deferred Tax Liabilities | - | - | - | - | - |
Other Non-Current Liabilities | - | - | - | - | - |
Total Non-Current Liabilities | 1.2B | 866.8M | 1.4B | 1.8B | 985.2M |
Total Liabilities | 6.9B | 6.3B | 7.9B | 10.4B | 8.7B |
Equity | |||||
Common Stock | 457.5M | 457.5M | 457.5M | 457.5M | 457.5M |
Retained Earnings | - | 18.3B | 14.6B | 11.3B | 6.8B |
Treasury Stock | - | - | - | - | - |
Other Equity | - | - | - | - | - |
Total Shareholders Equity | 42.2B | 36.0B | 32.1B | 28.6B | 23.9B |
Key Metrics | |||||
Total Debt | 1.1B | 945.4M | 1.3B | 1.7B | 1.1B |
Working Capital | 29.4B | 22.2B | 18.7B | 15.4B | 11.3B |
Balance Sheet Composition
Pfizer Cash Flow Statement From 2021 to 2025
Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|---|
Operating Activities | |||||
Net Income | 10.2B | 7.5B | 8.2B | 7.7B | 6.7B |
Depreciation & Amortization | - | - | - | - | - |
Stock-Based Compensation | 136.6M | 144.5M | 127.0M | 117.7M | 105.6M |
Working Capital Changes | 405.1M | -1.5B | 556.3M | 480.1M | 92.5M |
Operating Cash Flow | 9.1B | 4.5B | 8.1B | 7.9B | 6.6B |
Investing Activities | |||||
Capital Expenditures | 1.2B | 339.7M | -637.6M | -132.5M | -176.2M |
Acquisitions | - | 0 | 1.8B | 0 | - |
Investment Purchases | - | - | - | -6.1B | -5.0B |
Investment Sales | - | - | - | - | - |
Investing Cash Flow | 1.4B | 341.2M | 1.2B | -6.2B | -5.1B |
Financing Activities | |||||
Share Repurchases | - | - | - | - | - |
Dividends Paid | -1.6B | -1.8B | -3.0B | -1.6B | -15.2B |
Debt Issuance | - | - | - | - | - |
Debt Repayment | - | - | - | - | - |
Financing Cash Flow | -1.6B | -1.8B | -3.0B | -1.6B | -15.2B |
Free Cash Flow | 6.3B | 2.4B | 2.9B | 6.5B | 4.1B |
Net Change in Cash | 8.9B | 3.0B | 6.3B | 80.7M | -13.7B |
Cash Flow Trend
Pfizer Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
29.77
Forward P/E
29.84
Price to Book
5.42
Price to Sales
10.02
PEG Ratio
29.84
Profitability Ratios
Profit Margin
33.65%
Operating Margin
35.96%
Return on Equity
19.65%
Return on Assets
9.32%
Financial Health
Current Ratio
6.17
Debt to Equity
2.57
Beta
0.13
Per Share Data
EPS (TTM)
₹167.76
Book Value per Share
₹921.88
Revenue per Share
₹498.68
Peer Financial Comparison
Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
---|---|---|---|---|---|---|
pfizer | 228.5B | 29.77 | 5.42 | 19.65% | 33.65% | 2.57 |
GlaxoSmithKline | 455.2B | 47.81 | 23.33 | 47.54% | 25.41% | 0.51 |
Sanofi India Limited | 119.9B | 33.00 | 15.31 | 49.43% | 18.29% | 2.67 |
Sanofi Consumer | 119.5B | 59.51 | 46.41 | 66.30% | 27.62% | 11.01 |
Marksans Pharma | 95.6B | 25.12 | 3.88 | 16.73% | 14.51% | 12.93 |
Senores | 30.2B | 44.69 | 3.90 | 7.21% | 14.82% | 38.75 |
Financial data is updated regularly. All figures are in the company's reporting currency.